Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients

Antiviral Therapy

Volumn 10, Issue 3, 2005, Pages 423-429

  Laguno, Montse ^a   Milinkovic, Ana ^a   De Lazzari, Elisa ^a   Murillas, Javier ^a   Martínez, Esteban ^a   Blanco, Jose Luis ^a   Loncá, Montse ^a   Biglia, Alejandra ^a   Leon, Agatha ^a   García, Mercedes ^a   Larrousse, Maria ^a   García, Felipe ^a   Miró, Jose Maria ^a   Gatell, Jose Maria ^a   Mallolas, Josep ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; AMYLASE; CD4 ANTIGEN; CYCLOOXYGENASE 2; DIDANOSINE; EFAVIRENZ; LACTIC ACID; LAMIVUDINE; MITOCHONDRIAL DNA; NELFINAVIR; NEVIRAPINE; PANCREAS ENZYME; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TRIACYLGLYCEROL LIPASE; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT;

ADULT; AGE; ALCOHOL CONSUMPTION; ARTICLE; DIABETES MELLITUS; DRUG USE; ENZYME BLOOD LEVEL; FEMALE; GENDER; GENE EXPRESSION; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; INCIDENCE; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIPODYSTROPHY; LIVER FIBROSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MITOCHONDRIAL TOXICITY; MIXED INFECTION; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; STEATOSIS; VIRUS LOAD; CHEMICALLY INDUCED DISORDER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG ADMINISTRATION; DRUG COMBINATION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MITOCHONDRIAL DISEASES; PROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS;

EID: 20444460277     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Thomas DL, Vlahov D, Solomon L, Cohn S, Taylor E, Garfein R & Nelson KE. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995; 74:212-220.
2. Puoti M, Spinetti A, Ghezzi A, Donato F, Zaltron S, Putzolu V, Quiros-Roldan E, Zanini B, Casari S & Carosi G. Mortality for liver disease in patients with HIV infection: a cohort study. Journal of Acquired Immune Deficiency Syndromes 2000; 24:211-217.
3. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R & Snydman DR. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clinical Infectious Diseases 2001; 32:492-497.
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J & Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine 2002; 347:975-982.
5. Manns MP, McHutchinson JG, Gordon SC, Rutgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M & the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
6. Lafeuillade A, Hittinger G & Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357:280-281.
7. Salmon-Céron D, Chauvelot-Moachon L, Abad S, Silbermann B & Sogni P. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357:1803-1804.
8. Fleischer R, Boxwell D & Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clinical Infectious Diseases 2004; 38:79-80.
9. Allard JP, Aghdassi E, Chau J, Salit I & Walmsley S. Oxidative stress and plasma antioxidant micronutrients in humans with HIV infection. American Journal of Clinical Nutrition 1998; 67:143-147.
10. Polo R, Martinez S, Madrigal P & Gonzalez-Munoz M. Factors associated with mitochondrial dysfunction in circulating peripheral blood lymphocytes from HIV-infected people. Journal of Acquired Immune Deficiency Syndromes 2003; 34:32-36.
11. Barbaro G, Di Lorenzo G, Asti A, Ribersani M, Belloni G, Grisorio B, Filice G & Barbarini G. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. American Journal of Gastroenterology 1999; 94:2198-2205.
12. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D & Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16:1341-1349.
13. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wyonhoven B, Ting Wong H, Harris M, Harrigan PR, O'Shaughnessy MV & Montaner JS. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New England Journal of Medicine 2002; 346:811-820.
14. Walker UA, Bauerle J, Laguno M, Murillas J, Mauss S, Schmutz G, Setzer B, Miquel R, Gatell JM & Mallolas J. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39:311-317.
15. Kakuda TN & Brinkman K. Mitochondrial toxic effects and ribavirin. Lancet 2001; 357:1802-1803.
16. Brinkman K & Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiviral therapy? Current Opinion in Infectious Diseases 2000; 13:5-11.
17. Balzarini J, Lee CK, Herdewijn P & De Clercq E. Mechanism of potentiating effect of ribavirin on the activity of 2′,3′- dideoxyinosine against human immunodeficiency virus. Journal of Biological Chemistry 1991; 266:21509-21514.
18. Hartman NR, Ahluwalia GS, Cooney DA, Mitsuya H, Kageyama S, Fridland A, Broder S & Johns DG. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Molecular Pharmacology 1991; 40:118-124.
19. FDA Announcement. New Safety Information for Videx (Didanosine, ddI) Used with Ribavirin. 25 September 2002.
20. Hammond EL Sayer D, Nolan D, Walker UA, Ronde A, Montaner JS, Cote HC, Gahan ME, Cherry CL, Wesselingh SL, Reiss P & Mallal S. Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. Journal of Clinical Virology 2003; 27:97-110.
21. Gerard Y, Viget N, Yazdanpanah Y, Ajana F, de La Tribonniere X, Bocket L, Deuffic-Burban S, Dos Santos A, Ballester L & Mouton Y. Hyperlactataemia during antiretroviral therapy: incidences, clinical data and treatment. Therapie 2003; 58:153-158.
22. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P & Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clinical Infectious Diseases 2001; 33:1931-1937.
23. Glesby MJ & Jerber JG. Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity. AIDS Reader 2003; 13:344-348.
24. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM & Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122:366-375.
25. Moreno A, Quereda C, Moreno L, Perez-Elias MJ, Muriel A, Casado JL, Antela A, Dronda F, Navas E, Barcena R & Moreno S. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antiviral Therapy 2004; 9:133-138.
26. S Pol, Carrat F, Hor TR, Deshayes J, Banisadr F, Rosenthal E & Perronne C. High risk of mitochondriopathy in HIV/HCV co-infected patients under concomitant ddI/d4T and interferon (standard or pegylated IFN) /ribavirin treatments. 38th Annual Meeting of the European Association for the Study of the Liver. 3-6 July 2003, Geneva, Switzerland. Abstract 3530.00.